BNET Industries

BNET Pharma

Industry news and insights by Jim Edwards

Pfizer Paid Medical Director for State-Funded Anti-Smoking Campaign

By Jim Edwards | January 12th, 2009 @ 11:27 am

UPDATE: The doctor at the center of the report says his roll was misrepresented, and that there was no overlap between his time at Pfizer and the anti-smoking project he later led. See comments section below for full statement.

The medical director of a state-funded anti-smoking project in Wisconsin was on Pfizer’s payroll as a speaker for Chantix, the controversial anti-smoking drug, according to the Milwaukee Journal Sentinel. In 2007, the paper said, Dr. Eric Heiligenstein (pictured) put in 14 days for Pfizer and was paid $10,000 to $20,000. Heiligenstein also gave paid talks for Pfizer in 2006, the paper said.

Heiligenstein.jpgHeiligenstein, a University of Wisconsin-Madison psychiatrist, is also the medical director of the Wisconsin Nicotine Dependence Treatment Integration Project, according to this newsletter. The project is state-funded, according to this press release.

The relationships are potentially controversial for two reasons. First, there has been criticism that tax-funded anti-smoking efforts have been turned into sales pitches for anti-smoking drugs marketed by pharma companies. Some people believe quitting cold turkey is actually more effective than drugs.

Second, Chantix has been associated with unusual side effects (such as suicidal thoughts) and has been banned for some users, like airline pilots and truckers.

Side note: Heiligenstein is a bit of a blues guitarist. You can enjoy his music on his MySpace page here. The No.1 song listed on his page is “Baby Scratch My Back.”

Tags: Pfizer Inc., Director, Corporate Communications, Corporate Governance, Marketing, Business Operations, Corporate Law, Jim Edwards

Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools.

Email Jim Edwards or follow him on Twitter.
 
Reply to Story

BNET TalkbackShare your ideas and expertise on this topic

Subscribe to this discussion via Email or RSS

     
  • 1

    BNET's Jim Edwards

    02/18/09 | Report as spam

    RE: Pfizer Paid Medical Director for State-Funded Anti-Smoking Campaign

    From: Eric Heiligenstein

    Re: MJS article on conflict of interest.

    Although I followed up my phone interview with the MJS with two detailed emails that provided easily verifiable factual information, their article about me contains significant inaccuracies. While they did quote a few things I said, most of the important information I provided was left out, including the critical fact that I stopped doing promotional speaking for Pfizer in November 2007, prior to taking the Medical Director position for WiNTiP in January 2008. As written, the article implies that I have a conflict of interest. This is absolutely not the case. Moreover, WiNTiP is a 2-hour-per-week commitment, not a full-time position, as implied in the article.

    The article also appears to portray me as callous to individuals who have suffered serious adverse effects from Chantix. The article failed to mention that the majority of those presentations were given before the potential adverse side effects of the medication were known.

    It is regrettable that MJS readers did not get all the details needed to make an informed judgment.

    Sincerely,

    Eric Heiligenstein, MD

The following tags are supported in BNET comments:
<b></b> <i></i> <u></u> <pre></pre>

Leave a Reply

  1. You are currently a guest | Login?
advertisement
Go
advertisement
  • Click Here
  • Click Here
advertisement
AboutPharma Industry

BNET Pharma provides daily industry news coverage and insights for managers and executives about the major manufacturers of pharmaceuticals and medicine. In addition to detailed company profiles, we bring you critical analysis on new alliances and partnerships, new patents and products, mergers and acquisitions, cost management, investments and deal flow, and a host of other important business issues.